EARLY ONLINE RELEASE

This article was posted on the Archives Web site as an Early Online Release. Note: Due to the extremely time sensitive nature of the content of this article, it has not been copyedited or formatted per journal style. Changes or corrections may be made to this article when it appears in a future print issue of the Archives. Early Online Release articles are citable by using the Digital Object Identifier (DOI), a unique number given to every article.

The DOI for this manuscript is doi: 10.5858/arpa.2020-0389-SA

The final published version of this manuscript will replace the Early Online Release version at the above DOI once it is available.
Title: A comprehensive appraisal of laboratory biochemistry tests as major predictors of COVID-19 severity

Elena Aloisio, MD; Mariia Chibireva, MD; Ludovica Serafini, MD; Sara Pasqualetti, MSc; Felicia S. Falvella, MSc; Alberto Dolci, MD; Mauro Panteghini, MD

Clinical Pathology Unit, ASST Fatebenefratelli-Sacco, Milan, Italy (Dr. Aloisio, Dr. Chibireva, Dr. Serafini, Dr. Pasqualetti, Dr. Falvella, Dr. Dolci, Dr. Panteghini); Department of Biomedical and Clinical Sciences ‘Luigi Sacco’, University of Milan, Milan, Italy (Dr. Dolci, Dr. Panteghini)

Corresponding author:
Elena Aloisio, MD
Unità Operativa Complessa di Patologia Clinica
Azienda Socio-Sanitaria Territoriale Fatebenefratelli Sacco
Via G.B. Grassi 74
Milan, Italy
elena.aloisio@asst-fbf-sacco.it

The authors have no relevant financial interest in the products or companies described in this article.

Running Title: Lab predictors of COVID-19 severity
ABSTRACT

Context: A relevant portion of COVID-19 patients develop severe disease with negative outcomes. Several biomarkers have been proposed to predict COVID-19 severity, but no definite interpretative criteria have been established to date for stratifying risk.

Objective: To evaluate six serum biomarkers (C-reactive protein, lactate dehydrogenase, D-dimer, albumin, ferritin and cardiac troponin T) for predicting COVID-19 severity and to define related cut-offs able to aid clinicians in risk stratification of hospitalized patients.

Design: A retrospective study of 427 COVID-19 patients was performed. Patients were divided into groups based on their clinical outcome: non-survivors vs. survivors and patients admitted to intensive care unit vs. others. ROC curves and likelihood ratios were employed to define predictive cut-offs for evaluated markers.

Results: Marker concentrations at peak were significantly different between groups for both selected outcomes. At univariate logistic regression analysis, all parameters were significantly associated with higher odds of death and intensive care. At the multivariate analysis, high concentrations of lactate dehydrogenase and low concentrations of albumin in serum remained significantly associated with higher odds of death, while only low lactate dehydrogenase activities remained associated with lower odds of intensive care admission. The best cut-offs for death prediction were >731 U/L for lactate dehydrogenase and ≤18 g/L for albumin, while a lactate dehydrogenase activity <425 U/L was associated with a negative likelihood ratio of 0.10 for intensive treatment.

Conclusions: Our study identifies which biochemistry tests represent major predictors of COVID-19 severity and defines the best cut-offs for their use.

Key words: severe acute respiratory syndrome coronavirus 2; COVID-19; prognosis; biomarkers; albumin; cardiac troponin T; lactate dehydrogenase
INTRODUCTION

At the end of 2019, an outbreak of atypical pneumonia of unknown cause was detected in Wuhan, capital of the province of Hubei, China. The etiological agent of this disease was later identified to be a novel coronavirus, named “severe acute respiratory syndrome coronavirus 2” (SARS-CoV-2), phylogenetically similar but distinct from other coronaviruses known to cause disease in humans, such as human severe acute respiratory syndrome and Middle East respiratory syndrome. The disease caused by SARS-CoV-2, named COVID-19, has since spread worldwide warranting the recognition as a pandemic by the World Health Organization on March 11th, 2020.

Most patients infected with SARS-CoV-2 are asymptomatic or present with an uncomplicated mild illness characterized by fever, dry cough, nausea, asthenia, and myalgia. Up to 14% of patients, however, can evolve towards the development of a severe respiratory disease, characterized by radiological findings of interstitial pneumonia and progressively worsening respiratory impairment requiring ventilatory assistance. About 5% of subjects ultimately develop a full-on acute respiratory distress syndrome (ARDS), requiring admittance to an intensive care unit (ICU) to administer invasive mechanical ventilatory support. These patients are also at risk of developing sepsis, septic shock and multiorgan failure. Major risk factors for development of severe disease are old age, male sex, and comorbidities, such as metabolic and cardiovascular disease.

Many laboratory test results have been reported significantly altered in patients with severe COVID-19. In addition to the acute phase proteins, such as C-reactive protein (CRP), ferritin and procalcitonin, studies have reported significant differences in levels of hematological and hemostasis parameters, such as lymphocyte and neutrophil granulocyte count, and D-dimer, and in other biochemistry markers, such as lactate dehydrogenase (LDH), cardiac
troponins, serum albumin, aminotransferases, and creatinine. Most of these parameters are commonly requested in daily clinical practice, however, to the best of our knowledge, no specific interpretative criteria, i.e. cut-offs able to aid in the evaluation of COVID-19 severity, have been reported so far. The aim of this study was to obtain a comprehensive appraisal of the most performing laboratory biochemistry tests in predicting COVID-19 severity in a large group of patients and to define related cut-offs useful for their stratification in terms of prediction of ICU admission and mortality.
METHODS

Study Population

We performed a retrospective, observational study on adult (≥18 years old) COVID-19 patients admitted between February 21st and March 31st, 2020 to the ‘Luigi Sacco’ academic hospital in Milan, one of the two national reference centers for infectious diseases. Patients were hospitalized in one of the following isolation wards reserved exclusively to the COVID-19 care: one ICU, two infectious disease units, one pulmonology unit, and four low-medium intensity care wards. All patients had clinical and/or radiological findings highly suggestive for COVID-19 at admission and SARS-CoV-2 infection was confirmed by detection of viral RNA on nasopharyngeal material, using a real-time reverse transcription polymerase chain reaction method. The Institutional Review Board approved the study.

Analytical Methods

Patients’ data were extracted from the hospital information systems. CRP, LDH, D-dimer, albumin, ferritin, and cardiac troponin T (cTnT) results were collected. As more than one test result was available for each patient, the worst result of the whole hospitalization period was considered for analysis (i.e., the highest result for all evaluated analytes except for albumin, for which the lowest result was selected). CRP, albumin, and LDH were measured on the Alinity platform (Abbott Diagnostics) by using immunoturbidimetry (CRP and albumin) and enzymatic (LDH) assays, respectively. D-dimer was measured on the ACL TOP 750 platform (IL-Werfen) and results expressed in fibrinogen-equivalent units (FEU). Ferritin and cTnT were measured using a chemiluminescent microparticle immunoassay on the Alinity platform and a high-sensitivity electrochemiluminescence immunoassay on a Cobas e601 platform (Roche Diagnostics), respectively. Data about analytical performance of
employed methods were previously published. Adult reference intervals (all derived from previously performed ad hoc local studies) are: CRP, up to 10 mg/L; albumin, 35-50 g/L; LDH, 125-220 U/L; D-dimer, up to 500 µg/L FEU (≤50 years old) and up to the ‘age years x 10’ µg/L FEU (>50 years old); ferritin, 100-250 µg/L; and cTnT, up to 15 ng/L.

Conversion factors from conventional units to Système International (SI) units are: CRP, from mg/L to nmol/L multiply by 9.5238; albumin, from g/L to mmol/L multiply by 0.0150; LDH, from U/L to nkat/L multiply by 16.6667; ferritin, from µg/L to nmol/L multiply by 0.0022.

**Statistical Analysis**

Biomarkers were evaluated according to the following outcomes: 1) death during hospitalization (non-survivors) vs. hospital discharge after clinical recovery (survivors), and 2) hospitalization in ICU vs. hospitalization in non-intensive wards. Demographic, clinical and laboratory characteristics were compared between patients separated in these categories.

Data were reported as percentages for categorical variables and median with interquartile range (IQR) for quantitative variables. Differences between variables in different categories were assessed by applying chi-squared test (categorical) and Mann-Whitney rank-sum test (quantitative).

Optimum biomarker cut-offs both for predicting death and excluding necessity for intensive care were extrapolated from a receiver operating characteristic (ROC) analysis, by maximizing specificity (outcome 1) and sensitivity (outcome 2), respectively. Likelihood ratios (LR) and predictive values (PV) associated with selected cut-offs were then derived. Univariate logistic regression was used to estimate variables’ odds ratios (OR) and their 95% confidence intervals (CI) in relation to the selected outcome. A multivariate logistic regression model was then applied to variables significant at the univariate analysis. Final
selection of variables included in the multivariate model was done by applying a stepwise approach. A $P$ value <.05 denoted statistical significance. All analyses were performed using MedCalc software.
RESULTS

In the evaluated period, 518 COVID-19 patients were admitted. Of these, 91 patients were excluded from further analysis because they were still hospitalized as of April 13th, 2020, when we started the collection of data. A total of 427 COVID-19 patients with definite clinical outcomes was therefore included in the final analyses. Of these, 89 (20.8%) patients died during the hospitalization period, while 338 were discharged after clinical recovery. Furthermore, 47 (11.0%) patients of the 427 required admission to the ICU, while 380 stayed in non-intensive care COVID units along all hospitalization period. Median age for all patients was 61 years (IQR, 50-73 years), and 293 of the 427 (69%) of patients were male. Demographic and medical history data for the studied population are shown in Table 1. Information about the past medical history could not be retrieved for 18 patients (13 in the ICU group and 5 in the non-ICU group) who deceased suddenly. The most frequent comorbidity was hypertension, present in 134 of the 409 patients with complete data available, followed by cardiovascular disease (85 of the 409 patients, 21%) and diabetes mellitus (56 of the 409 patients, 14%). In non-survivors, age and the frequency of all comorbidities, except for human immunodeficiency virus infection more frequent in survivors, were significantly higher than in surviving patients. On the other hand, no significant differences in age and frequency of comorbidities were found between patients admitted to the ICU and other patients, except for cardiovascular disease, which was more frequent in the non-ICU group (Table 1).

Values of selected laboratory tests were significantly different between groups for both the examined outcomes (Table 2, Figures 1A-1F and 2A-2F). Figures 3A and 3B show ROC curves for the evaluated tests according to the ability to predict the two selected outcomes. For predicting patient death, cTnT displayed the best accuracy, with an area under the ROC
curve (AUC) of 0.94 (95% CI: 0.90 to 0.98), followed by LDH, albumin, and CRP (Table 3). The best cut-offs maximizing clinical specificity and minimizing false positive test results in predicting patient death are reported in Table 3 (and displayed in Figures 1A-1F and 2A-2F), together with the corresponding positive LR and positive PV. In this regard, the results showed a relevant capability for cTnT >30 ng/L (positive LR: 31.9; 95% CI 4.4 to 228.8) and LDH >731 U/L (positive LR: 19.7; 95% CI 9.1 to 42.7) to foresee death in COVID-19 patients. It should be however noted the wide CI associated to cTnT due to the relatively low number of patients (n=98) who underwent measurements of this biomarker. Given the relevant association found between elevated cTnT and mortality, we checked the death causes of the 35 deceased patients for whom cTnT was measured during hospitalization. For 34 of these patients (97%), the main cause of death was respiratory failure due to pneumonia complications, with no direct evidence of mortal cardiac events. Only one patient, who however had a relatively low peak cTnT measurement of 14 ng/L, died of cardiac arrest after the insurgence of a non-shockable arrhythmia unresponsive to manual cardiopulmonary resuscitation.

The best power to predict ICU admission was found for serum albumin, with an AUC of 0.89 (95% CI 0.84-0.94), followed by CRP and LDH (Table 4). Using a cut-off of ≥29 g/L, albumin displayed the best accuracy to exclude the need of ICU admission. Here, in evaluating the test performance, sensitivity was favored to minimize the risk of false negative results, i.e. patients with test results lower (higher for albumin) than cut-off that are actually admitted to ICU.

At univariate analysis, ORs for death during hospitalization were significantly higher for older patients and patients with concentrations of all evaluated tests over the selected cut-offs (under the selected cut-off for albumin) (Table 5). On the other hand, patient age was not a
significant predictor of ICU admission, whereas all the evaluated laboratory tests were (Table 6). At the multivariate analysis, done by including only the 72 patients who had complete data for all considered variables, age, high serum concentrations of LDH and low serum concentrations of albumin remained significantly associated with high OR of death, while only LDH concentrations <425 U/L were significantly associated with low OR for ICU admission (Table 5 and 6). After multivariate analysis, cTnT maintained a borderline significance ($P=.06$) as predictor of death.
DISCUSSION

Months after the initial spread of SARS-CoV-2-related disease in China, it is now evident from published studies that, together with age and other risk factors such as comorbidities, alterations of different laboratory markers can be useful to assess disease severity and risk of evolution towards critical stages. However, available studies only reported purely descriptive analyses of the studied populations and no clear interpretative criteria for commonly requested biochemistry parameters were defined for use in COVID-19 patients to predict negative outcomes with a defined probability. In our study, we depicted this probability by deriving LR and PV associated with selected cut-offs. Positive LR expresses the quotient between the probability that a value of the test overlapping the indicated cut-off is associated with the defined outcome and the probability that it does not associate with such outcome. Negative LR, on the other hand, expresses the quotient between the probability that a value of the test lower (higher in the case of albumin) than the indicated cut-off is associated with a negative outcome and the probability that it does not associate with such outcome. Positive and negative PV are two essential calculations that provide insight into the accuracy of positive or negative test results within the population tested. These values are based on the test sensitivity and specificity, but also incorporate and are dependent on the prevalence of selected outcomes in the studied population. In our study, positive PV reported in Table 3, last column, indicate the number of deceased COVID-19 patients that a test accurately identifies out of the total number of dead patients within our population. On the other hand, negative PV listed in Table 4 define the accurate detection of cases that did not require intensive treatment. Our cut-off values were specifically selected to have a high specificity, i.e. rule-in ability, in detecting patients at risk of in-hospital death and a high sensitivity, i.e. rule-out ability, in detecting patients not at risk of ICU admission.
To our knowledge, this study is the largest case-series of COVID-19 patients in Italy so far and one of the largest worldwide. In terms of population description, our findings are similar to those from other studies, mainly carried out on Chinese population. Among laboratory biochemistry tests, we included in our analysis those biomarkers, already proposed in previous descriptive studies, that appear to cover a relevant portion of pathophysiological mechanisms potentially influencing the disease severity. CRP and ferritin are acute phase proteins that may reflect the hyperinflammatory state induced by SARS-CoV-2 active infection; LDH activity in serum may reflect both lung damage and more widespread tissue damage; D-dimer is associated with hemostasis disorders and disseminated intravascular coagulation, which are frequent in COVID-19 patients; serum albumin levels are related to hepatic and renal functions as well as the nutritional status, which are often compromised during long and complicated hospitalizations; finally, cardiac troponin levels may reflect both the presence of a pre-existing cardiovascular condition, which is one of the major risk factors for developing severe COVID-19 (Table 1), and the insurgence of cardiac complications directly related to the viral infection or to the compromised pulmonary function.

In terms of death prediction, the only test with an AUC above 0.90, the limit indicating high global accuracy, was cTnT. COVID-19 patients with a peak cTnT value >30 ng/L (corresponding to two times the upper reference limit selected at the 99th percentile of the reference population) had a chance of dying more than 30 times higher than other patients. On the other hand, the cTnT value for predicting ICU admission was relatively poor. This is probably due to the fact that COVID-19 patients are generally admitted to the ICU following the development of respiratory impairment and ARDS, while the development of cardiac complications caused by SARS-CoV-2 infection, such as myocarditis, usually does not
require intensive care treatment. Previous studies have shown that cardiac troponin I concentrations exceeding the 99th percentile upper reference limit can be observed in 8–12% of COVID-19 patients. Only one study has previously measured cTnT, detecting elevated concentrations, defined as above the 99th percentile upper reference limit, in 27.8% of evaluated patients and showing that myocardial injury, as detected by a cTnT increase, is significantly associated with fatal outcome of COVID-19. Unfortunately, the assay used in the study was not specified and a fixed cut-point for marker application not stated, so results were not directly replicable in other settings. Our data confirm that COVID-19 patients displaying myocardial injury, revealed by elevated cTnT concentrations, are at high risk of death and enlarge the previous information by indicating the best biomarker cut-off associated with this outcome. Due to the relatively low number of patients tested, cTnT reached only borderline significance when a multivariable model was applied. The best fitting variables for death prediction at multivariate logistic regression were patient age, LDH, and albumin concentrations. Markedly altered levels of these two laboratory parameters, reflecting a general impairment of the patient’s health status and organ functions, independently predicted death during hospitalization.

The tests that had the higher power for excluding need of intensive care were serum albumin, CRP, and LDH, with an AUC of 0.88-0.89. Patients for which these analytes did not show marked variations during the whole hospitalization period had a low probability of requiring admission to ICU. This is not surprising as these markers reflect a combination of heightened inflammatory state and organ tissue damage and/or disfunction that could lead to worsening of clinical conditions and require intensive treatment. The possible role of LDH as the most powerful clinical predictor of outcome worsening in COVID-19 patients is
indicated by the fact that this test is the only biomarker that remains significantly associated with both selected outcomes at the multivariate logistic regression analysis.

One of the strengths of our study is that all evaluated biomarkers, except for D-dimer for which harmonization initiatives are still ongoing,\textsuperscript{10, 11} were determined using methodologies which harmonization has been verified and validated. Ferraro et al previously stressed how the issues of measurement standardization and harmonization represent an absolute priority for optimizing health care.\textsuperscript{29} Only the use of assays providing harmonized results will allow the use of common reference intervals and decision limits, enabling the universal application of results of clinical studies undertaken in different locations or times and permitting their unambiguous interpretation. Accordingly, all the selected cut-offs reported in this study can be directly applied in other situations providing that the related institutions also use assays that produce harmonized results. In regards to this, it is worth mentioning that, in this study, serum albumin was measured with an immunoturbidimetric assay, which is fully specific for the protein measurement contrary to colorimetric methods, such as those based on protein dye-binding, e.g. the bromocresol green methods, which are in use in the majority of clinical institutions worldwide.\textsuperscript{30} This explains why albumin concentrations reported in our study appear to be lower than other data reported in literature for COVID-19 patients.\textsuperscript{18, 20} On the other hand, we are aware that the programs about harmonization of D-dimer assays are ongoing and that higher order reference materials are still not available. However, preliminary studies comparing different D-dimer assays seem to support a certain grade of comparability between results.\textsuperscript{10, 11} It should also be noted that another confounding issue for D-dimer test is represented by the lack of homogeneity in reporting units of measurement. In this study, results were reported as µg/L FEU, which relate the
mass of D-dimer to the mass of fibrinogen, as previously recommended. Reporting values using alternative units could result in erroneous classification of normal and elevated results.

The major limitation of our study is represented by its retrospective nature. However, as the results were obtained on a large population of over 450 COVID-19 patients, it is safe to say that they are statistically robust and may represent a significant aid in decision making for prioritized treatment and more aggressive strategies in this still poorly known disease.

Another potential confounder is represented by the possible inability of admitting to the ICU all the patients who would have required intensive care due to ICU capacity constraints. However, due to an effective territorial organization, no major obstacles to ICU admission when needed were experienced during the study period in our institution.
CONCLUSIONS

Performing risk stratification in COVID-19 patients based solely on clinical features is often difficult as signs and symptoms are usually lacking specificity. From the results of this study, it appears that some laboratory biochemistry parameters may represent an invaluable aid in identifying patients with low risk of disease progression and consequent need of ICU admission, and, at the opposite, patients with higher risk of mortality. The interpretative criteria for laboratory tests defined in this study were specifically selected to obtain accurate rule-out of patients who did not need intensive care treatment and rule-in of patients at higher risk of death. These two sets of test cut-offs should be optimally used in combination to perform an accurate evaluation of this serious disease.
REFERENCES

1. Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. *N Engl J Med*. 2020;382(8):727-733.

2. Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. *N Engl J Med*. 2020;382(18):1708-1720.

3. World Health Organization. Coronavirus disease (COVID-19) pandemic, www.who.int/emergencies/diseases/novel-coronavirus-2019. Accessed May 13th 2020.

4. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet*. 2020;395(10229):1054-1062.

5. Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. *JAMA*. 2020;323(11):1061-1069.

6. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet*. 2020;395(10223):497-506.

7. Braga F, Panteghini M. Derivation of performance specifications for uncertainty of serum C-reactive protein measurement according to the Milan model 3 (state of the art) [Published online ahead of print, June 29th 2020]. *Clin Chem Lab Med*. 2020. https://doi.org/10.1515/cclm-2020-0532.

8. Infusino I, Panteghini M. Serum albumin: accuracy and clinical use. *Clin Chim Acta*. 2013;419:15-18

9. Aloisio E, Frusciante E, Pasqualetti S, et al. Traceability validation of six enzyme measurements on the Abbott Alinity c analytical system *Clin Chem Lab Med*. 2020;58(8):1250–1256.

10. Meijer P, Haverkate F, Kluft C, de Moerloose P, Verbruggen B, Spannagl M. A model for the harmonization of test results of different quantitative D-dimer methods. *Thromb Haemost*. 2006;95(3):567-572.

11. Jennings I, Woods TA, Kitchen DP, Kitchen S, Walker ID. Laboratory D-dimer measurement: improved agreement between methods through calibration. *Thromb Haemost*. 2007;98(5):1127-1135.

12. Ferraro S, Mozzi R, Panteghini M. Revaluating serum ferritin as a marker of body iron stores in the traceability era. *Clin Chem Lab Med*. 2012;50(11):1911-1916.
13. Saenger AK, Beyrau R, Braun S, et al. Multicenter analytical evaluation of a high-sensitivity troponin T assay. *Clin Chim Acta*. 2011;412(9-10):748-754.

14. Pepe MS, Feng Z, Janes H, Bossuyt PM, Potter JD. Pivotal evaluation of the accuracy of a biomarker used for classification or prediction: standards for study design. *J Natl Cancer Inst*. 2008;100(20):1432–1438.

15. Lippi G. Plebani M. Laboratory abnormalities in patients with COVID-19 infection *Clin Chem Lab Med*. 2020;58(7):1131-1134.

16. Bonetti G, Manelli F, Patroni A, et al. Laboratory predictors of death from coronavirus disease 2019 (COVID-19) in the area of Valcamonica, Italy. *Clin Chem Lab Med*. 2020;58(7):1100-1105.

17. Zhang JJ, Dong X, Cao YY, et al. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China [Published online ahead of print, February 19th 2020]. *Allergy*. 2020. https://doi.org/10.1111/all.14238.

18. Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. *Lancet*. 2020;395(10223):507-513.

19. Xu XW, Wu XX, Jiang XG, et al. Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series. *BMJ*. 2020;368:m606.

20. Liu Y, Yang Y, Zhang C, et al. Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury. *Sci China Life Sci*. 2020;63(3):364-374.

21. Liu F, Li L, Xu M, et al. Prognostic value of interleukin-6, C-reactive protein, and procalcitonin in patients with COVID-19. *J Clin Virol*. 2020;127:104370.

22. Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ. COVID-19: consider cytokine storm syndromes and immunosuppression. *Lancet*. 2020;395(10229):1033-1034.

23. Panteghini M, Bais R. Serum enzymes. In: Rifai N, Horvath AR, Wittwer CT eds. *Tietz Textbook of Clinical Chemistry and Molecular Diagnostics, 6th ed.*, St. Louis: Elsevier Saunders; 2018:404-434.

24. Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. *J Thromb Haemost*. 2020;18(4):844-847.
25. Lippi G, Lavie CJ, Sanchis-Gomar F. Cardiac troponin I in patients with coronavirus disease 2019 (COVID-19): evidence from a meta-analysis [Published online ahead of print, March 10th 2020]. Prog Cardiovasc Dis. 2020. https://10.1016/j.pcad.2020.03.001.

26. Guo T, Fan Y, Chen M, et al. Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19). JAMA Cardiol. 2020;e201017.

27. Swets JA. Measuring the accuracy of diagnostic systems. Science. 1988;240(4857):1285-1293.

28. Dolci A, Braga F, Valente C, Guzzetti S, Panteghini M. Impact of implementation of the high-sensitivity cardiac troponin T assay in a university hospital setting. Clin Chem. 2011;57(8):1211-1212.

29. Ferraro S, Braga F, Panteghini M. Laboratory medicine in the new healthcare environment. Clin Chem Lab Med. 2016;54(4):523-533.

30. Bachmann LM, Yu M, Boyd JC, Bruns DE, Miller WG. State of harmonization of 24 serum albumin measurement procedures and implications for medical decisions. Clin Chem. 2017;63(3):770–779.

31. Lippi G, Cervellin G, Casagranda I, Morelli B, Testa S, Tripodi A. D-dimer testing for suspected venous thromboembolism in the emergency department. Clin Chem Lab Med. 2014;52(5):621-628.
FIGURE LEGENDS

Figure 1. Box and whiskers plots showing the distribution of results of C-reactive protein (CRP) (A), lactate dehydrogenase (LDH) (B), D-dimer (C), albumin (D), ferritin (E) and troponin T (F) in studied COVID-19 patients, according to outcome 1 [death during hospitalization (non-survivors) vs. hospital discharge after clinical recovery (survivors)]. The dashed lines indicate the cut-offs selected by maximizing the specificity, i.e. reducing the number of false positives, of each test. Note that, except for CRP and albumin, the scale in y-axis is logarithmic.

Figure 2. Box and whiskers plots showing the distribution of results of C-reactive protein (CRP) (A), lactate dehydrogenase (LDH) (B), D-dimer (C), albumin (D), ferritin (E) and troponin T (F) in studied COVID-19 patients according to outcome 2 [hospitalization in intensive care unit (ICU) vs. hospitalization in non-intensive wards]. The dashed lines indicate the cut-offs selected by maximizing the sensitivity, i.e. reducing the number of false negatives, of each test. Note that, except for CRP and albumin, the scale in y-axis is logarithmic.

Figure 3. Receiver operating characteristic (ROC) curves for the evaluated tests according to the ability to predict the two selected outcomes. Panel A refers to the death outcome. Panel B refers to the intensive care unit admission outcome.
Table 1. Baseline characteristics of COVID-19 patients included in the study.

|                     | Total | Non-survivors | Survivors | P   | ICU | Non-ICU | P   |
|---------------------|-------|---------------|-----------|-----|-----|---------|-----|
| **Age [median (IQR)]** | 61 (50-73) | 73 (67-80) | 58 (48-69) | <.001 | 64 (57-70) | 61 (50-73) | .74 |
| **Sex [no./total (%)]** |       |               |           |     |     |         |     |
| Female              | 134/427 (31) | 19/89 (21) | 115/338 (34) | .03 | 6/47 (13) | 128/380 (34) | .006 |
| Male                | 293/427 (69) | 70/89 (79) | 223/338 (66) |     | 41/47(87) | 252/380 (66) |     |
| **Comorbidities [no./total (%)]** |       |               |           |     |     |         |     |
| Hypertension        | 134/409 (33) | 33/71 (47) | 101/338 (30) | .01 | 11/34 (32) | 123/375 (33) | .89 |
| Cardiovascular disease | 85/409 (21) | 31/71 (44) | 54/338 (16) | <.001 | 3/34 (9) | 82/375 (22) | .009 |
| Diabetes mellitus   | 56/409 (14) | 17/71 (24) | 39/338 (12) | .01 | 5/34 (15) | 51/375 (14) | .94 |
| Chronic respiratory disease | 49/409(12) | 14/71 (20) | 35/338 (10) | .047 | 3/34 (9) | 46/375 (12) | .75 |
| Obesity             | 10/409 (2) | 6/71 (9) | 4/338 (1) | .002 | 1/34 (3) | 9/375 (2) | .69 |
| HIV infection       | 9/409 (2) | 0/71 (0) | 9/338 (3) | .02 | 1/34 (3) | 8/375 (2) | .76 |

*Definition of abbreviations: ICU, intensive care unit; IQR, interquartile range; HIV, human immunodeficiency virus.*
Table 2. Laboratory findings in COVID-19 patients included in the study.

|                  | Non-survivors   | Survivors       | P    |
|------------------|-----------------|-----------------|------|
|                  | No. Median (IQR)| No. Median (IQR)|      |
| C-reactive protein (mg/L) | 89 258 (188-355) | 338 93 (38-165) | <.001 |
| LDH (U/L)        | 89 671 (528-885) | 332 340 (267-436) | <.001 |
| D-Dimer (µg/L FEU) | 75 12,227 (3070-29,031) | 294 1173 (673-3370) | <.001 |
| Albumin (g/L)    | 83 20 (17-24)    | 307 28 (25-32)   | <.001 |
| Ferritin (µg/L)  | 54 2526 (1210-3762) | 189 504 (433-1573) | <.001 |
| Troponin T (ng/L)| 35 32 (17-68)    | 63 9 (6-11)      | <.001 |

|                  | ICU             | Non-ICU         | P    |
|------------------|-----------------|-----------------|------|
|                  | No. Median (IQR)| No. Median (IQR)|      |
| C-reactive protein (mg/L) | 47 313 (208-387) | 380 108 (42-188) | <.001 |
| LDH (U/L)        | 47 660 (553-907) | 374 353 (274-472) | <.001 |
| D-Dimer (µg/L FEU) | 47 11,870 (3614-28,919) | 322 1263 (726-3896) | <.001 |
| Albumin (g/L)    | 47 18 (16-20)    | 381 27 (24-32)   | <.001 |
| Ferritin (µg/L)  | 33 2062 (1247-3473) | 210 884 (458-1762) | <.001 |
| Troponin T (ng/L)| 17 27 (14-58)    | 81 10 (7-18)     | <.001 |

Definition of abbreviations: IQR, interquartile range; LDH, lactate dehydrogenase; FEU, fibrinogen-equivalent units; ICU, intensive care unit.
Conversion factors to Système International (SI) units: CRP, from mg/L to nmol/L multiply by 9.5238; albumin, from g/L to mmol/L multiply by 0.0150; LDH, from U/L to nkat/L multiply by 16.6667; ferritin, from µg/L to nmol/L multiply by 0.0022.
Table 3. ROC curve analysis and diagnostic ability of evaluated tests to predict in-hospital death in studied COVID-19 patients using the best cut-off maximizing clinical specificity.

| Test          | AUC (95% CI) | Selected cut-off | Specificity (95% CI) | LR+* (95% CI) | PPV (95% CI) |
|---------------|--------------|------------------|----------------------|---------------|--------------|
| Troponin T    | 0.94 (0.90-0.98) | >30 ng/L         | 0.98 (0.91-1.00)     | 31.9 (4.4-228.8) | 0.89 (0.58-1.00) |
| LDH           | 0.89 (0.86-0.93) | >731 U/L         | 0.98 (0.96-0.99)     | 19.7 (9.1-42.7) | 0.84 (0.70-0.93) |
| Albumin       | 0.87 (0.84-0.91) | ≤18 g/L          | 0.97 (0.94-0.98)     | 12.2 (6.3-23.7) | 0.76 (0.61-0.88) |
| C-reactive protein | 0.83 (0.83-0.91) | >303 mg/L        | 0.96 (0.93-0.98)     | 10.4 (5.8-18.7) | 0.73 (0.59-0.85) |
| D-Dimer       | 0.84 (0.80-0.89) | >16,280 µg/L FEU | 0.96 (0.93-0.98)     | 10.7 (5.6-20.3) | 0.74 (0.58-0.86) |
| Ferritin      | 0.77 (0.70-0.84) | >2824 µg/L       | 0.93 (0.88-0.96)     | 6.3 (3.5-11.2)  | 0.62 (0.45-0.78) |

* The strength of the indication for the presence of the selected outcome provided by the positive result of the test is relevant when LR+≥10, modest when 5≤LR+<10, and poor when 2≤LR+<5.14

Definition of abbreviations: AUC, area under the ROC curve; CI, confidence interval; LR+, positive likelihood ratio; PPV, positive predictive value; LDH, lactate dehydrogenase; FEU, fibrinogen-equivalent units.

Conversion factors to Système International (SI) units: CRP, from mg/L to nmol/L multiply by 9.5238; albumin, from g/L to mmol/L multiply by 0.0150; LDH, from U/L to nkat/L multiply by 16.6667; ferritin, from µg/L to nmol/L multiply by 0.0022.
Table 4. ROC curve analysis and diagnostic ability of evaluated tests to exclude the need of admission in intensive care unit in COVID-19 patients during hospitalization using the best cut-off maximizing clinical sensitivity.

| Test             | AUC (95% CI) | Selected cut-off | Sensitivity (95% CI) | LR−* (95% CI) | NPV (95% CI) |
|------------------|--------------|------------------|----------------------|---------------|--------------|
| Albumin          | 0.89 (0.84-0.94) | ≥29 g/L           | 0.98 (0.89-1.00)     | 0.07 (0.01-0.50) | 0.99 (0.95-1.00) |
| C-reactive protein | 0.88 (0.84-0.93) | <141 mg/L        | 0.94 (0.83-0.99)     | 0.10 (0.03-0.30) | 0.99 (0.94-1.00) |
| LDH              | 0.88 (0.84-0.92) | <425 U/L          | 0.94 (0.93-0.99)     | 0.10 (0.03-0.30) | 0.99 (0.97-1.00) |
| D-Dimer          | 0.84 (0.78-0.89) | <1704 µg/L FEU    | 0.94 (0.93-0.99)     | 0.10 (0.03-0.30) | 0.99 (0.96-1.00) |
| Troponin T       | 0.77 (0.66-0.88) | <9 ng/L           | 0.94 (0.71-1.00)     | 0.13 (0.02-0.90) | 0.98 (0.88-1.00) |
| Ferritin         | 0.73 (0.64-0.82) | <404 µg/L         | 0.97 (0.84-1.00)     | 0.15 (0.02-1.00) | 0.98 (0.89-1.00) |

* The strength of the indication for the absence of the selected outcome provided by the negative result of the test is relevant when LR− ≤0.10, modest when 0.10< LR− ≤0.20, and poor when 0.20< LR− ≤0.50.14

Definition of abbreviations: AUC, area under the ROC curve; CI, confidence interval; LR−, negative likelihood ratio; NPV, negative predictive value; LDH, lactate dehydrogenase; FEU, fibrinogen-equivalent units.
Table 5. Univariate and multivariate logistic regression analyses for predictors of death during hospitalization of COVID-19 patients.

|                          | Univariate analysis | Multivariate analysis |
|--------------------------|---------------------|-----------------------|
|                          | Odds ratio (95% CI) | P         | Odds ratio (95% CI) | P         |
| Age                      | 1.09 (1.07-1.12)    | <.001    | 1.14 (1.03-1.27)    | .01       |
| C-reactive protein       | 12.1 (6.39-22.8)    | <.001    | -                    | -         |
| LDH                      | 33.0 (14.0-78.0)     | <.001    | 161.5 (2.28-11,422.8)| .02       |
| D-Dimer                  | 13.1 (6.55-26.2)    | <.001    | -                    | -         |
| Albumin                  | 19.6 (9.09-42.3)     | <.001    | 46.0 (3.54-596.8)    | .003      |
| Ferritin                 | 10.8 (5.02-23.1)     | <.001    | -                    | -         |
| Troponin T               | 32.3 (6.81-153.2)    | <.001    | 10.3 (0.95-111.2)    | .06       |

Definition of abbreviations: CI, confidence interval; LDH, lactate dehydrogenase.
Table 6. Univariate and multivariate logistic regression analyses for predictors of admission in intensive care unit of COVID-19 patients during hospitalization.

|                      | Univariate analysis |                      | Multivariate analysis |                      |
|----------------------|---------------------|----------------------|-----------------------|----------------------|
|                      | Odds ratio (95% CI) | P        | Odds ratio (95% CI) | P        |
| Age                  | 1.01 (0.98-1.02)    | .86      | -                     | -                     |
| C-reactive protein   | 0.04 (0.01-0.14)    | <.001    | -                     | -                     |
| LDH                  | 0.03 (0.01-0.12)    | <.001    | 0.06 (0.01-0.54)      | .01                  |
| D-Dimer              | 0.04 (0.01-0.14)    | <.001    | -                     | -                     |
| Albumin              | 0.10 (0.03-0.33)    | <.001    | -                     | -                     |
| Ferritin             | 0.12 (0.02-0.94)    | .04      | -                     | -                     |
| Troponin T           | 0.12 (0.01-0.94)    | .004     | -                     | -                     |

Definition of abbreviations: CI, confidence interval; LDH, lactate dehydrogenase.
